News

Header image for Determine which is a rare cancer clinical trial, you can see doctors testing cancer therapies and a mother of a child suffering of cancer.

DETERMINE is a cutting edge UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.

Since launching in December 2021, the DETERMINE trial has hit many milestones on the way to providing much needed treatment options for people with rare cancers, including treating its 100th patient.

Find out more about DETERMINE's successes

News

Sky News covered the Target National genetic screening trial and spoke to Pamela Garner-Jones who was diagnosed with cervical cancer in 2021. Through TARGET National, Pamela was matched to a treatment on our DETERMINE trial and has since seen her tumour shrink by two thirds and symptoms improve.

Press releases

Read the story of one patient (from the Observer)

Observer Story

News

DETERMINE is finalist in one of the categories of the SCRIPT AWARD: COMMUNITY PARTNERSHIP OF THE YEAR

READ about the SCRIPT AWARD categories

Press releases

DETERMINE is open in Scotland

Press release in The Herald

Press release in the Independent

Press release in The Times

Press release in the Evening Standard

Press release in The National

News

DETERMINE has received the Foster Age Inclusivity Research (FAIR) for Adolescents and Young Adults (AYA) Stamp as recognition of good model of age inclusivity led by academics and supported by different pharmaceutical companies.

Read about the DETERMINE award: FAIR for AYA STAMP